FUSEN PHARM: VOLUNTARY ANNOUNCEMENTCLINICAL TRIAL APPLICATION FOR THE CLASS 1.1 INNOVATIVETRADITIONAL CHINESE MEDICINE 'SY617' HAS BEEN ACCEPTED
FUSEN PHARM: SUPPLEMENTAL ANNOUNCEMENT TO THE 2023 CORPORATE GOVERNANCE REPORT
FUSEN PHARM: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024
FUSEN PHARM: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2024
FUSEN PHARM: VOLUNTARY ANNOUNCEMENT APPLICATION FOR LAUNCHING "ENZALUTAMIDE SOFT CAPSULES" BEING ACCEPTED
FUSEN PHARM: POLL RESULTS OF THE ANNUAL GENERAL MEETINGHELD ON 28 MAY 2024
FUSEN PHARM: SUPPLEMENTAL ANNOUNCEMENTDISCLOSEABLE TRANSACTIONSUBSCRIPTION OF INTEREST IN LIMITED LIABILITY PARTNERSHIPAND ENTERING INTO THE LIMITED PARTNERSHIP AGREEMENT
FUSEN PHARM: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2024
FUSEN PHARM: FORM OF PROXY FOR USE AT THE ANNUAL GENERAL MEETING(or at any adjournment thereof)
FUSEN PHARM: NOTICE OF ANNUAL GENERAL MEETING
FUSEN PHARM: PROPOSALS FORGENERAL MANDATES TO ISSUE SHARESAND SELL TREASURY SHARESAND REPURCHASE SHARES,RE-ELECTION OF DIRECTORS,RE-APPOINTMENT OF AUDITORSANDNOTICE OF ANNUAL GENERAL MEETING
FUSEN PHARM: ANNUAL REPORT 2023
FUSEN PHARM: VOLUNTARY ANNOUNCEMENTAPPLICATION FOR LAUNCHING"COMPOUND POTASSIUM PHOSPHATE INJECTION" BEING ACCEPTED
FUSEN PHARM: Next Day Disclosure Return
FUSEN PHARM: Next Day Disclosure Return
FUSEN PHARM: DISCLOSEABLE TRANSACTIONSUBSCRIPTION OF INTEREST IN LIMITED LIABILITY PARTNERSHIPAND ENTERING INTO THE LIMITED PARTNERSHIP AGREEMENT
FUSEN PHARM: VOLUNTARY ANNOUNCEMENTAPPLICATION FOR LAUNCHING"METFORMIN EMPAGLIFLOZIN TABLETS (I)" ACCEPTED
FUSEN PHARM: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
FUSEN PHARM: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
FUSEN PHARM: NOTICE OF BOARD MEETING
No Data